Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00704730 · ClinicalTrials.gov registry record · Phase 3
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
A Phase 3 study of Thyroid Cancer, sponsored by Exelixis.
- Completed
- Registry status
- Phase 3
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT00704730 is a Phase 3 study of Thyroid Cancer that has completed, run by Exelixis. The registered enrollment target is 330 participants, above the 275-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 17 states.
The verdict
NCT00704730, a Phase 3 study of Thyroid Cancer, has completed, sponsored by Exelixis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this research study is to evaluate the progression-free survival (PFS) with XL184 as compared with placebo (an inactive substance) in subjects with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Subjects will be randomized to receive XL184 or placebo in a 2:1 ratio. XL184 is an investigational drug that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration. The Clinical Steering Committee for this study, comprised of study doctors who specialize in medullary thyroid cancer, has provided guidance regarding the design of the study. The committee includes: Douglas Ball, MD, Barry Nelkin, PhD, Martin Schlumberger, MD and Steven Sherman, MD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG XL184
Study Locations (20)
California
- - Burbank
- UCLA - Los Angeles
- Stanford Cancer Center - Stanford
Missouri
- Capitol Comprehensive Cancer Care Clinic and Research Institute - Jefferson City
- Washington University School of Medicine - St Louis
Alabama
- University of Alabama at Birmingham, Comprehensive Cancer Center - Birmingham
Arizona
- TGEN Clinical Research Service at Scottsdale Healthcare - Scottsdale
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- University of Colorado Cancer Center - Aurora
Connecticut
- Yale University, School of Medicine - New Haven
District of Columbia
- Washington Cancer Institute - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2008-06 |
| Est. Completion | 2020-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00704730
The ClinicalTrials.gov registry entry for NCT00704730 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 275-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (20% higher). The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00704730 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Missouri, Alabama.
Frequently Asked Questions
What is clinical trial NCT00704730 about?
NCT00704730 is a clinical study titled "Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer". The purpose of this research study is to evaluate the progression-free survival (PFS) with XL184 as compared with placebo (an inactive substance) in subjects with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Subjects will be randomized to receive XL184 or placebo in ...
What is the current status of trial NCT00704730?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 330 participants. The study started on 2008-06. Estimated completion is 2020-09.
What conditions does trial NCT00704730 study?
This clinical trial studies the following conditions: Thyroid Cancer.
What interventions are being tested in trial NCT00704730?
The interventions under investigation include: Placebo (DRUG), XL184 (DRUG).
Who is sponsoring clinical trial NCT00704730?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00704730 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer
RECRUITING · Phase 3
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
COMPLETED · Phase 3
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.